Crohn's Disease

Patients with inflammatory bowel disease reported improvement in symptoms using a personalized specific carbohydrate diet, according to a presenter at the Crohn’s and Colitis Congress.

Despite the considerable progress made in the care of inflammatory bowel disease, current therapies are “still plateauing” in terms of response and remission, according to the keynote speaker at the Crohn’s and Colitis Congress.

Although the rate of surgery for inflammatory bowel disease has declined significantly in the era of biologic therapy, “it is still occurring,” according to a presenter at the Crohn’s and Colitis Congress.

A presenter at the Crohn’s and Colitis Congress discussed the latest research on COVID-19 in patients with inflammatory bowel disease.

It is important for health care providers to ask patients with inflammatory bowel disease about sexual dysfunction and other reproductive concerns, according to a presentation at the Crohn’s and Colitis Congress.

Intensive drug therapy improved symptoms, stricture-associated inflammation and stricture morphology among patients with Crohn’s disease, according to research published in The Lancet Gastroenterology & Hepatology.

Histologic activity was not associated with recurrence in patients who were in complete endoscopic remission after ileocolonic resection for Crohn’s disease, according to new data.

Early infliximab therapy initiation following surgery may result in long-term fistula healing among patients with perianal fistulizing Crohn’s disease, according to research published in BMC Gastroenterology.

In older patients with inflammatory bowel disease, adverse event rates were comparable between those treated with Stelara and those who received placebo, according to a recent analysis.

Patients with inflammatory bowel disease who responded to biologic therapy experienced improvement in sexual dysfunction, according to research presented at the ACG Annual Scientific Meeting.